Radioimunotherapy ytrium-90 (90Y)-ibritumomab tiuxetanam in patients with folicular non-hodgkin lymphoma – experience of one departmen
2010
Abstract
Radioimunotherapy ytrium-90 (90Y)in patients with folicular non-hodgkin lymphoma; combination of chemotherapy and immunotherapy; cross fire effect; antigen CD20; B-lymphocytes;